載入...
Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma
The immunomodulatory drug lenalidomide is used in patients with follicular lymphoma (FL) with the aim of stimulating T-cell antitumor immune response. However, little is known about the effects of lenalidomide on T-cell biology in vivo in patients with FL. We thus undertook an extensive longitudinal...
Na minha lista:
| 發表在: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095143/ https://ncbi.nlm.nih.gov/pubmed/33877296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003774 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|